Should all women be vaccinated against human papillomavirus and what effect will this have on screening programs?

References

• Ferlay J, Bray F, Pisani P, Parker DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5. IARC Press, Lyon, France (2001).
   Google Scholar
• Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. IARC Scientific Publication 155. Vol 8. IARC Press, Lyon, France.
   Google Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papilloma virus types associated with cervical cancer. N. Engl. J. Med.348, 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Castellsague X, Diaz M, de Sanjose S et al. Bosch FX, for the International Agency for Research on Cancer Multicentre Cervical Cancer Study Group. The worldwide human papilloma virus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl Cancer Inst.98(5), 303–315 (2006).
   PubMed Web of Science ®Google Scholar
• Koutsky L, Ault KA, Wheeler CM et al. A controlled trial of human papilloma type 16 vaccine. N. Engl. J. Med.347(21), 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Frazer I, Cox JT, Mayeauz EJ Jnr et al. Advances in prevention of cervical cancer and other human papilloma virus related diseases. Pediatric Infect. Dis. J.25, S65–S81 (2006).
   PubMed Web of Science ®Google Scholar
• Munoz N for the Future II Study Group. Efficacy of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against cervical intraepithelial neoplasia grades 1–3 and adenocarcinoma in situ; a combined analysis. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN). Paris, France, April 23–26, 2006 (Abstract).
   Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilloma virus types 16 and 18: follow up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic disease. Vaccine24, 26–34 (2006).
   Web of Science ®Google Scholar
• Schwartz TF. An AS04-containing human papilloma virus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old. Presented at: American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA, June 2–6, 2006.
   Google Scholar
• Baseman J, Koutsky LA. The epidemiology of human papilloma virus infections. J. Clin. Virol.32, 16–24 (2005).
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H et al. Incidence, duration and determinants of cervical human papilloma virus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis.190, 2077–2087 (2004).
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papilloma virus. Vaccine24, 16–22 (2006).
   PubMed Web of Science ®Google Scholar
• Franceschi S, Herrero R, Clifford GM et al. Variations in the age-specific curves of human papilloma virus prevalence in women worldwide. Int. J. Cancer119(11), 2677–2684 (2006).
   PubMed Web of Science ®Google Scholar
• Sellors J, Karwalajtys TL, Kaczorowshi J et al. Incidence, clearance and predictors of human papilloma virus infection in women. CMAJ168, 421–425 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson A, Mercer CH, Erens B et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet358, 1835 (2001).
   PubMed Web of Science ®Google Scholar
• de Visser RO, Smith AM, Rissel CE, Richters J, Grulich AE. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust. NZ J. Public Health27(2), 146–154 (2003).
   PubMed Web of Science ®Google Scholar
• Schwartz T, Dubin GO, HPV Vaccine Study Investigators for Adult Women, GlaxoSmithKline Biologicals. AS04-adjuvanted HPV 16/18 L1 vaccine for preventing cervical cancer is highly immunogenic and well tolerated in women over 25 years of age. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.24(18S), 1008 (2006).
   Google Scholar
• Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papilloma virus on vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet. Gynecol.108(6), 1361–1368 (2006).
   PubMed Web of Science ®Google Scholar
• Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol.5, 149–157 (2005).
   Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Lazcano E, Samakoses R. A randomised controlled trial to evaluate the safety and immunogenicity of a quadrivalent human papilloma virus (types 6, 11, 16, 18) L1 virus-like particle vaccine in preadolescents and adolescents. Presented at: The European Society for Paediatric Infectious Diseases. Basel, Switzerland, May 3–5, 2006 (Abstract).
   Google Scholar
• Barnabas RV, Laukkanen P, Koskela P et al. The epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLOS Med.3(5), e138 (2006).
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Idanpaan-Heikkila I, Lunnas T et al. Population-based enrolment of adolescents in a long-term follow up trial of human papilloma virus vaccine efficacy. Int. J. STD AIDS17(4), 237–246 (2006).
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papilloma virus vaccine to screening programs. JAMA290(6), 781–789 (2003).
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papilloma virus vaccination programs. Emerg. Infect. Disc.10(11), 1915–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost–effectiveness of a human papilloma virus 16/18 vaccine. J. Natl Cancer Inst.96(8), 604–615 (2004).
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Lawrence WF, Gaffikin L et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J. Natl Cancer Inst.94(19), 1469–1483 (2002).
   PubMedGoogle Scholar
• Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. Cost–effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med.353(20), 2158–2168 (2005).
   PubMed Web of Science ®Google Scholar